Continuation Fund

A continuation fund is a new investment vehicle launched by a general partner to hold one or more portfolio companies past the end of the original fund’s term. Rather than selling the company at the mandated fund expiration date, the GP rolls it into fresh capital structure, giving high-conviction assets more runway and allowing LPs to choose whether to stay invested.

Why funds have fixed lifespans

A standard private equity fund has a defined term — usually 10 years, with 2–3 year extension options. This deadline serves multiple purposes. It forces the GP to harvest returns and cash out LPs, limiting the dead capital syndrome that plagued older buyout funds. It also creates urgency: knowing the fund must exit by year 12, the GP is incentivized to improve the portfolio company and prepare a sale or IPO.

But sometimes the deadline and asset readiness don’t align. A company that hit the market in year 10 as a distressed vendor would fetch a fire-sale price. An asset that’s finally profitable, growing at 30 per cent annually, and with two more strategic buyers circling next spring — that’s the opposite of ready. A forced sale destroys value.

Continuation funds solved this problem in the late 1990s and became standard practice by the 2010s.

The mechanics of a rollover

Picture Fund I, launched in 2015 with a 10-year term ending in 2025. In 2023, the GP sits with three portfolio companies: Software Inc. (maturing, ready for sale), Hardware Co. (stable, lower growth), and BioTech Ltd. (pre-revenue, but in clinical trials). Fund I’s 10-year clock is ticking.

Rather than sell all three into a weak market and distribute cash, the GP creates Fund II — Continuation, a new vehicle. The GP proposes rolling BioTech Ltd. into Fund II at fair market value. Hardware Co. can stay in Fund I (funded by its own remaining capital), or some LPs might roll it into Fund II as well. Software Inc. gets sold on Fund I’s timeline — no continuation needed.

Fund I’s LPs receive a choice: “Accept a cash distribution for your pro-rata share of Fund II’s equity, or roll your stake into Fund II.” Most large LPs can choose. Smaller LPs may have less negotiating power. Some continuation funds are fully opt-in; others are structured as a “majority roll” with dissenting LPs forced to take a cash equivalent.

The GP also typically invests fresh capital into Fund II — a new management fee calculation and a fresh carry structure. If Fund I carried at 20 per cent, Fund II will too. The GP is essentially resetting the profit clock.

Valuation and pricing fairness

The critical gotcha: at what price does the portfolio company move from Fund I to Fund II? If the GP low-balls the valuation, Fund I’s LPs get shortchanged, and Fund II’s incoming LPs overpay. If the GP inflates it, Fund II’s LPs carry artificial loss reserves from day one.

Best practice is an independent third-party valuation. Most large transactions hire a Big Four firm or specialist to appraise the company at fair market value — what a willing buyer and seller would agree to at arm’s length. This appraisal price becomes the “rollover price,” and LPs buying in at that value understand they’re neither getting a gift nor overpaying.

Controversy erupts when a GP structures the rollover in its own favour. If the GP rolls into Fund II but doesn’t itself co-invest at the same price, and the valuation later proves too high, Fund II’s LP returns suffer. Large endowments and pension funds now insist on explicit fairness opinions and GP co-investment at the rolled valuation.

The carry reset and fee acceleration

A continuation fund carries fresh management fees and a fresh carry arrangement. This can dramatically improve GP economics — the GP essentially gets another 10 years of carry on assets it already owns.

Consider a scenario. Fund I invests $100 million in Company X in year 2. By year 9, Company X is worth $300 million, but it’s not yet ready to sell. The GP takes a $300 million valuation and rolls Company X into Fund II at that price. Fund II investors buy in at $300 million cost basis, and the GP receives a fresh 20 per cent carry on any appreciation above $300 million.

For Fund I’s LPs, this is mixed. They’ve already benefited from the $200 million paper gain. They can exit at fair value and redeploy capital. But they also miss the next upleg if Company X grows to $500 million in Fund II’s hold period — the GP and new Fund II LPs capture that growth.

When continuation funds fail

Continuation funds are also used — sometimes controversially — to extend struggling assets. If a company underperforms and likely won’t reach its original exit multiple by the fund deadline, the GP might propose a continuation fund to “give the asset more time.” This is tactically honest (more time might help) but also self-serving: it keeps the fee stream alive and delays the reckoning.

The worst-case scenario: a series of back-to-back continuations, each funded by new LPs unaware of prior shortfalls, effectively kicking a zombie asset down the road for 15 years. Sophisticated LPs now scrutinize continuation proposals carefully, demanding evidence that the GP believes in the upside, not that it’s hiding time.

Distribution and fund dynamics

When Fund I LPs opt into Fund II, they receive equity in the continuation fund in place of a cash distribution. From a tax perspective, this can be attractive — it defers the capital gains event and lets the LP remain invested. From a portfolio management view, it concentrates capital (the LP owns more of fewer companies) and requires fresh diligence into the GP’s continuation fund’s strategy and fee structure.

Some LPs use continuations to consolidate: rather than holding 20 positions across three funds, they roll into one continuation fund and simplify their portfolio.

See also